Investigating how genetic variations affect antibody therapies in Type 1 Diabetes
Fcy Receptor-Mediated Pharmacogenomics of Antibody Therapies in Type 1 Diabetes
This study is looking at how your genes might affect how well antibody treatments work for people who have just been diagnosed with Type 1 Diabetes, to help find out who might benefit the most from these therapies.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-10949606 on NIH RePORTER |
What this research studies
This research focuses on understanding how genetic differences in Fc gamma receptors (FcγR) may influence the effectiveness of antibody therapies for individuals recently diagnosed with Type 1 Diabetes (T1D). By examining these genetic variants, the study aims to determine if they affect the body's response to treatments that target immune cells responsible for the destruction of insulin-producing pancreatic β-cells. The approach involves analyzing patient samples and correlating genetic data with treatment outcomes to identify potential predictors of therapy success.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals recently diagnosed with Type 1 Diabetes who are considering antibody therapy.
Not a fit: Patients with long-standing Type 1 Diabetes or those not eligible for antibody therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective antibody therapies for patients with Type 1 Diabetes.
How similar studies have performed: Previous research has shown that genetic variations can significantly impact the effectiveness of antibody therapies in other autoimmune diseases, suggesting a promising avenue for this investigation.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Shapiro, Melanie R — University of Florida
- Study coordinator: Shapiro, Melanie R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.